fruquintinib
Trade name: Fruzaqla
Small moleculeapprovedFast Track FDA
Approved
Nov 8, 2023
Clinical trial activity
147 trials · 59 clinical orgs · 1 marketing orgs
Phase 1
27
Phase 2
117
Phase 3
13
Phase 4
4
Earliest trial started Jan 1, 2011 (NCT01645215)
Timeline
Indications
Approved for
Studied for
- Adenocarcinoma · Phase 2
- Angiogenesis Inhibitors · Phase 2
- Biliary Tract Neoplasms · Phase 2
- Breast Neoplasms · Phase 4
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Renal Cell · Phase 2/Phase 3
- Chemotherapy, Adjuvant · Phase 2
- Colonic Neoplasms · Phase 3
- Colorectal Neoplasms · Phase 4
- DNA Mismatch Repair · Phase 2
- Drug Interactions · Phase 1
- Drugs, Investigational · Phase 2
- Drug Therapy · Phase 2
- Endometrial Neoplasms · Phase 3
- Esophageal Neoplasms · Phase 2
- Esophageal Squamous Cell Carcinoma · Phase 2
- Food-Drug Interactions · Phase 1
- Healthy Volunteers · Phase 1
- Immune Checkpoint Inhibitors · Phase 2
- Immunotherapy · Phase 1/Phase 2
- Kidney Failure, Chronic · Phase 1
- Liver Diseases · Phase 1
- Liver Neoplasms · Phase 2
- Lung Neoplasms · Phase 2
- Maintenance · Phase 2
- Neoplasm Metastasis · Phase 1/Phase 2
- Neoplasm, Residual · Phase 2
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 2
- Paclitaxel · Phase 2
- Pancreatic Neoplasms · Phase 2
- Patient Safety · Phase 4
- Pharmacology · Phase 1
- Rectal Neoplasms · Phase 2/Phase 3
- Sarcoma · Phase 2
- Stomach Neoplasms · Phase 3
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
Mechanism of action
Vascular endothelial growth factor receptor inhibitor
Approval history
- approvedPriority reviewFast trackNov 8, 2023
Chemistry & pharmacology
Loading structure…
SMILES
CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12- Mol. weight
- 393.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4303214 ↗
- ChEMBLCHEMBL3545339 ↗
Also known as
- fruquintinib
- fruquintinib
- fruquintinib
- fruquintinib
- fruquintinib
- fruquitinib
- hmpl-013
- hmpl-013
- hmpl-013
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07124858 | N/A | Mar 1, 2026 | Federation Francophone de Cancerologie Digestive |
| NCT07286695 | Phase 2 | Dec 31, 2025 | Chinese Academy of Medical Sciences |
| NCT07270991 | Phase 3 | Dec 31, 2025 | Federation Francophone de Cancerologie Digestive, Takeda |
| NCT07229872 | Phase 2 | Dec 31, 2025 | Harbin Medical University |
| NCT07150403 | Phase 2 | Dec 31, 2025 | Federation Francophone de Cancerologie Digestive |
| NCT07261709 | Phase 2 | Dec 1, 2025 | Sun Yat-Sen University |
| NCT07235293 | Phase 2 | Nov 15, 2025 | Kahr Medical, Novotech |
| NCT07257653 | Phase 2 | Oct 21, 2025 | Zhejiang University |
| NCT07170982 | Phase 2 | Oct 15, 2025 | Sun Yat-Sen University |
| NCT07011576 | Phase 2 | Sep 29, 2025 | SCRI Development Innovations, Takeda |
| NCT07136077 | Phase 2 | Sep 18, 2025 | BeOne Medicines, University of Texas at Houston |
| NCT06992258 | Phase 2 | Sep 15, 2025 | Criterium, Inc. |
| NCT07130903 | Phase 2 | Sep 10, 2025 | THERABIONIC INC., Wayne State University |
| NCT07042685 | Phase 2 | Aug 31, 2025 | Methodist Cancer Center, Houston, Texas, Takeda, The University of Texas, Dallas |
| NCT07025850 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2025 | Anyang Regional Hospital, Fudan University |
| NCT07051785 | Phase 2 | Jul 7, 2025 | Huazhong University of Science and Technology |
| NCT06973421 | Phase 2 | Jul 1, 2025 | Fudan University |
| NCT06977061 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2025 | Nanchang University |
| NCT07003022 | Phase 2 | Jun 1, 2025 | Fudan University |
| NCT06985316 | N/A | May 19, 2025 | Huazhong University of Science and Technology |
Showing 20 of 147 trials
Page 1 / 8
Organizations
Research & Development (59)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fudan University | Academic/Hospital | 30 | 23 | 4 | 2011 |
| Hutchison MediPharma | For profit | 25 | 20 | 4 | 2011 |
| Sun Yat-Sen University | Academic/Hospital | 14 | 10 | 2 | 2012 |
| Huazhong University of Science and Technology | Academic/Hospital | 12 | 11 | 3 | 2019 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 9 | 9 | 2 | 2020 |
| Jiao Tong University | Academic/Hospital | 8 | 6 | 3 | 2014 |
| Fujian Medical University | Academic/Hospital | 5 | 5 | 2 | 2022 |
| Sichuan University | Academic/Hospital | 5 | 5 | 1 | 2019 |
| Takeda | For profit | 5 | 2 | 4 | 2024 |
| University of Washington | Academic/Hospital | 5 | 4 | 3 | 2022 |
| BeOne Medicines | For profit | 4 | 1 | 1 | 2021 |
| Henan Medical University | Academic/Hospital | 4 | 3 | 1 | 2021 |
| Nanjing Medical University | Academic/Hospital | 4 | 4 | 1 | 2021 |
| People's Liberation Army of China | Government | 4 | 3 | 2 | 2014 |
| Zhejiang University | Academic/Hospital | 4 | 2 | 2 | 2021 |
| Federation Francophone de Cancerologie Digestive | Academic/Hospital | 3 | 3 | 3 | 2025 |
| Nanchang University | Academic/Hospital | 3 | 3 | 3 | 2023 |
| Peking University | Academic/Hospital | 3 | 3 | 3 | 2022 |
| Xiamen University | Academic/Hospital | 3 | 2 | 2 | 2021 |
| Genor BioPharma Co., Ltd. | For profit | 2 | 2 | 1 | 2019 |
59 organizations
Page 1 / 3